Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events
Audience: Endocrinology, Cardiology [UPDATED 02/04/2011] FDA notified healthcare professionals and patients that information on the cardiovascular risks (including heart attack) of rosiglitazone has been added to the physician labeling and patient…
No related posts.




facebook
rss
twitter